[HTML][HTML] Estrogen signaling and its potential as a target for therapy in ovarian cancer
The estrogen receptor (ER) has functionality in selected ovarian cancer subtypes and
represents a potential target for therapy. The majority (> 80%) of high grade serous, low …
represents a potential target for therapy. The majority (> 80%) of high grade serous, low …
[HTML][HTML] Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label …
Background Low-grade serous carcinoma of the ovary or peritoneum is characterised by
MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high …
MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high …
[HTML][HTML] Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications
H Li, Y Liu, Y Wang, X Zhao, X Qi - Oncology reports, 2021 - spandidos-publications.com
Ovarian cancer (OC) remains the leading cause of mortality due to gynecological
malignancies. Epidemiological studies have demonstrated that steroid hormones released …
malignancies. Epidemiological studies have demonstrated that steroid hormones released …
[HTML][HTML] Exosomal metastasis‑associated lung adenocarcinoma transcript 1 promotes angiogenesis and predicts poor prognosis in epithelial ovarian cancer
JJ Qiu, XJ Lin, XY Tang, TT Zheng, YY Lin… - International journal of …, 2018 - ncbi.nlm.nih.gov
Exosomes mediate cell-cell crosstalk in cancer progression by transferring their molecular
cargos, including long noncoding RNAs (lncRNAs). Metastasis‑associated lung …
cargos, including long noncoding RNAs (lncRNAs). Metastasis‑associated lung …
[HTML][HTML] Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome
RL Hollis, JP Thomson, B Stanley… - Nature …, 2020 - nature.com
Endometrioid ovarian carcinoma (EnOC) demonstrates substantial clinical and molecular
heterogeneity. Here, we report whole exome sequencing of 112 EnOC cases following …
heterogeneity. Here, we report whole exome sequencing of 112 EnOC cases following …
MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma
B Manning-Geist, S Gordhandas, YL Liu, Q Zhou… - Clinical Cancer …, 2022 - AACR
Purpose: To characterize the somatic mutational landscape, investigate associations
between genetic alterations and clinical outcomes, and determine the prevalence of …
between genetic alterations and clinical outcomes, and determine the prevalence of …
Genetically defined, syngeneic organoid platform for developing combination therapies for ovarian cancer
The paucity of genetically informed, immunocompetent tumor models impedes evaluation of
conventional, targeted, and immune therapies. By engineering mouse fallopian tube …
conventional, targeted, and immune therapies. By engineering mouse fallopian tube …
[HTML][HTML] Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment
C Xintaropoulou, C Ward, A Wise, S Queckborner… - BMC cancer, 2018 - Springer
Background Novel therapeutic approaches are required to treat ovarian cancer and
dependency on glycolysis may provide new targets for treatment. This study sought to …
dependency on glycolysis may provide new targets for treatment. This study sought to …
[HTML][HTML] First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open-Cancer Horizons round-table discussion
S Banerjee, A Gonzalez-Martin, P Harter, D Lorusso… - ESMO open, 2020 - Elsevier
ABSTRACT Poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the
latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The …
latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The …
Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
Purpose: The abundance and effects of structural variation at BRCA1/2 in tumors are not
well understood. In particular, the impact of these events on homologous recombination …
well understood. In particular, the impact of these events on homologous recombination …